User profiles for J. Lieberman
Jay LiebermanProfessor of Medicine. The University of Tennessee Health Sciences Center Verified email at uthsc.edu Cited by 4655 |
The role of growth factors in the repair of bone: biology and clinical applications
JR Lieberman, A Daluiski, TA Einhorn - JBJS, 2002 - journals.lww.com
➤ There are a number of potential clinical applications for growth factors in the enhancement
of bone repair, including acceleration of fracture-healing, treatment of established …
of bone repair, including acceleration of fracture-healing, treatment of established …
Prevention of venous thromboembolism
…, W Geerts, JA Heit, M Knudson, JR Lieberman… - Chest, 1998 - journal.chestnet.org
The rationale for prophylaxis of venous thromboembolism (VfE) is based on the clinically silent
nature of the disease, the relatively high prevalence among hospitahzed patients, and the …
nature of the disease, the relatively high prevalence among hospitahzed patients, and the …
Anaphylaxis—a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis
…, DM Lang, ES Lang, JA Lieberman, J Portnoy… - Journal of Allergy and …, 2020 - Elsevier
Anaphylaxis is an acute, potential life-threatening systemic allergic reaction that may have a
wide range of clinical manifestations. Severe anaphylaxis and/or the need for repeated …
wide range of clinical manifestations. Severe anaphylaxis and/or the need for repeated …
[HTML][HTML] Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty
…, W Ageno, LC Borris, JR Lieberman… - … England Journal of …, 2008 - Mass Medical Soc
Background We investigated the efficacy of rivaroxaban, an orally active direct factor Xa
inhibitor, in preventing venous thrombosis after total knee arthroplasty. Methods In this …
inhibitor, in preventing venous thrombosis after total knee arthroplasty. Methods In this …
Anaphylaxis—a practice parameter update 2015
…, S Kemp, D Khan, D Ledford, J Lieberman… - Annals of Allergy …, 2015 - annallergy.org
This is the fourth iteration of this parameter entitled “The Diagnosis and Management of
Anaphylaxis.” The first anaphylaxis parameter was published in 1998 and the last in 2010. The …
Anaphylaxis.” The first anaphylaxis parameter was published in 1998 and the last in 2010. The …
The effect of regional gene therapy with bone morphogenetic protein-2-producing bone-marrow cells on the repair of segmental femoral defects in rats
JR Lieberman, A Daluiski, S Stevenson, LA JOLLA… - JBJS, 1999 - journals.lww.com
Background: Recombinant human bone morphogenetic proteins (rhBMPs) can induce bone
formation, but the inability to identify an ideal delivery system limits their clinical application. …
formation, but the inability to identify an ideal delivery system limits their clinical application. …
COVID-19: pandemic contingency planning for the allergy and immunology clinic
…, D Mack, AK Ellis, D Lang, J Lieberman… - The Journal of Allergy …, 2020 - Elsevier
In the event of a global infectious pandemic, drastic measures may be needed that limit or
require adjustment of ambulatory allergy services. However, no rationale for how to prioritize …
require adjustment of ambulatory allergy services. However, no rationale for how to prioritize …
Osteonecrosis of the hip: management in the 21st century.
JR Lieberman, DJ Berry, MA Mont… - Instructional course …, 2003 - europepmc.org
Osteonecrosis of the femoral head is a progressive condition that often leads to collapse of
the femoral head. The ultimate goal in the treatment for osteonecrosis of the hip is …
the femoral head. The ultimate goal in the treatment for osteonecrosis of the hip is …
The risk of allergic reaction to SARS-CoV-2 vaccines and recommended evaluation and management: a systematic review, meta-analysis, GRADE assessment, and …
…, D Lang, D Ledford, M Levin, J Lieberman… - The Journal of Allergy …, 2021 - Elsevier
Concerns for anaphylaxis may hamper severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
immunization efforts. We convened a multidisciplinary group of international …
immunization efforts. We convened a multidisciplinary group of international …
Bone morphogenetic protein-2: biology and applications.
…, MR Urist, KM Lyons, JR Lieberman - … Research (1976-2007 …, 1996 - journals.lww.com
Bone morphogenetic protein-2 is a low molecular weight glycoprotein, classified as a
morphogen. The sine qua non of bone morphogenetic protein is consistently reproducible …
morphogen. The sine qua non of bone morphogenetic protein is consistently reproducible …